Home Tags Immunogenicity

Tag: immunogenicity

RemeGen’s RC88 Receives US FDA Fast Track Designation

The United States Food and Drug Administration has granted Fast Track Designation for China-based RemeGen's RC88, a mesothelin (MSLN)-targeting antibody-drug conjugate (ADC). The investigational drug is intended for the treatment of patients diagnosed with platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.

Chinese Regulator Conditionally Approves Disitamab Vedotin in Advanced or Metastatic Gastric...

Disitamab vedotin (爱地希®/Aidixi®; Previously known as RC48; Remegen Biosciences) has been granted conditional marketing approval by the National Medical Products Administration (NMPA; 国家药品监督管理局) of...

Antitope and Synthon Collaborate In Assessing the Potential Immunogenicity of Candidate...

Cambridge (UK) based Antitope, a subsidiary of Abzena, has signed an agreement to  collaborate with Synthon Biopharmaceuticals, a global pharmaceutical company based in Nijmegen,...

X